Overview
DCOY market data
Price History
DCOY price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.79 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.58 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.32 – $415.80 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2.7 · P/B 0.71 · P/S 0.58.
Company news
Decoy Therapeutics Files Prospectus For Offering 3.767M Common Shares On Behalf Of Common ShareholdersBenzinga · Jul 10, 2026, 8:35 PM
Crude Oil Gains 2%; Comcast Shares Spike HigherBenzinga · Jun 29, 2026, 4:35 PM
Decoy Stock Rises After Announcing Up to $21 Million Private Placement FinancingBenzinga · Jun 29, 2026, 2:00 PM
Nasdaq Jumps More Than 1%; Comcast Shares Spike HigherBenzinga · Jun 29, 2026, 1:45 PM
Market-Moving News for June 29thBenzinga · Jun 29, 2026, 11:15 AM
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving PremarketBenzinga · Jun 29, 2026, 11:05 AM
8-K filing — Decoy Therapeutics Inc. (DCOY)SEC EDGAR · Jun 29, 2026, 10:03 AM
Decoy Therapeutics Announced The Execution Of A Strategic Development Initiative Designed To Support The Advancement Of The Company's Designable Multi-antiviral Candidates Into Phase 1 First-in-human And Phase 2a Human Proof-of-concept StudiesBenzinga · Jun 1, 2026, 11:09 AM
Decoy Therapeutics Q1 EPS $(4.18) Misses $(4.08) EstimateBenzinga · May 8, 2026, 10:19 PM